# Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

> **NCT06761976** · — · AVAILABLE · sponsor: **Bayer**

## Conditions studied

- Advanced Non-small Cell Lung Cancer
- Cancer

## Interventions

- **DRUG:** Sevabertinib

## Key facts

- **NCT ID:** NCT06761976
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761976, "Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06761976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*